Therapeutic modulation of epigenetic drivers of drug resistance in ovarian cancer

Therapeutic Advances in Medical Oncology

Volumn 2, Issue 5, 2010, Pages 319-329

  Zeller, Constanze ^a   Brown, Robert ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

CpG islands; DNA methylation; drug resistance; epigenetics; histones; ovarian cancer; therapies

Indexed keywords

3 DEAZANEPLANOCIN A; 4 [N (2 HYDROXYETHYL) N [2 (3 INDOLYL)ETHYL]AMINOMETHYL]CINNAMOHYDROXAMIC ACID; 5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; BELINOSTAT; BRCA1 PROTEIN; CARBOPLATIN; CISPLATIN; CYTIDINE; DEATH ASSOCIATED PROTEIN KINASE; DEPSIPEPTIDE; DNA; DNA METHYLTRANSFERASE 1; FANCONI ANEMIA GROUP F PROTEIN; HISTONE METHYLTRANSFERASE; HYDRALAZINE; MG 98; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; N (2 AMINOPHENYL) 4 [4 (3 PYRIDINYL) 2 PYRIMIDINYLAMINOMETHYL]BENZAMIDE; N PHTHALOYLTRYPTOPHAN; PACLITAXEL; PANOBINOSTAT; PIVALOYLOXYMETHYL BUTYRATE; POLYCOMB GROUP PROTEIN; PROCAINAMIDE; PROCAINE; PROTEIN MLH1; ROMIDEPSIN; SK 7041; SK 7068; TRICHOSTATIN A; TUBACIN; TUMOR MARKER; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID; VORINOSTAT;

APOPTOSIS; BREAST CANCER; CANCER CHEMOTHERAPY; CHEMOSENSITIVITY; CLINICAL TRIAL; COLON CANCER; CPG ISLAND; DISEASE ASSOCIATION; DNA METHYLATION; DNA REPAIR; DRUG RESISTANCE; EPIGENETICS; GENE EXPRESSION; GENE MUTATION; GENE SILENCING; HUMAN; LEUKEMIA; LUNG NON SMALL CELL CANCER; OVARY CANCER; PHENOTYPE; PRIORITY JOURNAL; REVIEW; T CELL LYMPHOMA; TUMOR SUPPRESSOR GENE;

EID: 78649297210     PISSN: 17588340     EISSN: None     Source Type: Journal    
DOI: 10.1177/1758834010375759     Document Type: Review

References (80)

1. Agarwal, R. and Kaye, S.B. ( 2003) Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer 3: 502-516.
2. Appleton, K., Mackay, H.J., Judson, I., Plumb, J.A., McCormick, C., Strathdee, G. et al. (2007) Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors. J Clin Oncol 25: 4603-4609.
3. Bachmann, I.M., Halvorsen, O.J., Collett, K., Stefansson, I.M., Straume, O., Haukaas, S.A. et al. (2006) EZH 2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. J Clin Oncol 24: 268-273.
4. Batty, N., Malouf, G.G. and Issa, J.P. (2009) Histone deacetylase inhibitors as anti-neoplastic agents. Cancer Lett 280: 192-200.
5. Bird, A. ( 2002) DNA methylation patterns and epigenetic memory. Genes Dev 16: 6-21.
6. Bird, A.P. ( 1996) The relationship of DNA methylation to cancer. Cancer Surv 28: 87-101.
7. Bolden, J.E., Peart, M.J. and Johnstone, R.W. ( 2006) Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 5: 769-784.
8. Broxterman, H.J., Gotink, K.J. and Verheul, H.M. (2009) Understanding the causes of multidrug resistance in cancer: a comparison of doxorubicin and sunitinib. Drug Resist Updat 12: 114-126.
9. Brueckner, B., Garcia Boy, R., Siedlecki, P., Musch, T., Kliem, H.C., Zielenkiewicz, P. et al. (2005) Epigenetic reactivation of tumor suppressor genes by a novel small-molecule inhibitor of human DNA methyltransferases. Cancer Res 65: 6305-6311.
10. Brueckner, B., Kuck, D. and Lyko, F. ( 2007) DNA methyltransferase inhibitors for cancer therapy. Cancer J 13: 17-22.
11. Cameron, E.E., Bachman, K.E., Myohanen, S., Herman, J.G. and Baylin, S.B. ( 1999) Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 21: 103-107.
12. Carter, H., Chen, S., Isik, L., Tyekucheva, S., Velculescu, V.E., Kinzler, K.W. et al. (2009) Cancer-specific high-throughput annotation of somatic mutations: computational prediction of driver missense mutations. Cancer Res 69: 6660-6667.
13. Cass, I., Baldwin, R.L., Varkey, T., Moslehi, R., Narod, S.A. and Karlan, B.Y. ( 2003) Improved survival in women with BRCA-associated ovarian carcinoma. Cancer 97: 2187-2195.
14. Cohen, O., Inbal, B., Kissil, J.L., Raveh, T., Berissi, H., Spivak-Kroizaman, T. et al. (1999) DAP-kinase participates in TNF-alpha- and Fas-induced apoptosis and its function requires the death domain. J Cell Biol 146: 141-148.
15. Dai, W., Teodoridis, J.M., Graham, J., Zeller, C., Huang, T.H., Yan, P. et al. (2008) Methylation Linear Discriminant Analysis (MLDA) for identifying differentially methylated CpG islands. BMC Bioinformatics 9: 337.
16. Duckett, D.R., Bronstein, S.M., Taya, Y. and Modrich, P. ( 1999) hMutSalpha and MutLalpha dependent phosphorylation of p 53 in response to DNA methylator damage. Proc Natl Acad Sci USA 96: 12384-12388.
17. Duvic, M., Talpur, R., Ni, X., Zhang, C., Hazarika, P., Kelly, C. et al. (2007) Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 109: 31-39.
18. Edwards, S.L., Brough, R., Lord, C.J., Natrajan, R., Vatcheva, R., Levine, D.A. et al. (2008) Resistance to therapy caused by intragenic deletion in BRCA2. Nature 451: 1111-1115.
19. Egger, G., Liang, G., Aparicio, A. and Jones, P.A. ( 2004) Epigenetics in human disease and prospects for epigenetic therapy. Nature 429: 457-463.
20. Ehrlich, M. ( 2006) Cancer-linked DNA hypomethylation and its relationship to hypermethylation. Curr Top Microbiol Immunol 310: 251-274.
21. Fenaux, P., Mufti, G.J., Hellstrom-Lindberg, E., Santini, V., Finelli, C., Giagounidis, A. et al. (2009) Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 10: 223-232.
22. Ferrandina, G., Bonanno, G., Pierelli, L., Perillo, A., Procoli, A., Mariotti, A. et al. (2008) Expression of CD133-1 and CD133-2 in ovarian cancer. Int J Gynecol Cancer 18: 506-514.
23. Fiskus, W., Wang, Y., Sreekumar, A., Buckley, K.M., Shi, H., Jillella, A. et al. (2009) Combined epigenetic therapy with the histone methyltransferase EZH 2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells. Blood 114: 2733-2743.
24. Garcia-Manero, G., Kantarjian, H.M., Sanchez-Gonzalez, B., Yang, H., Rosner, G., Verstovsek, S. et al. (2006) Phase 1 / 2 study of the combination of 5aza-2'-deoxycytidine with valproic acid in patients with leukemia. Blood 108: 3271-3279.
25. Garcia-Manero, G., Yang, H., Bueso-Ramos, C., Ferrajoli, A., Cortes, J., Wierda, W.G. et al. (2008) Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. Blood 111: 1060-1066.
26. Ghoshal, K., Datta, J., Majumder, S., Bai, S., Kutay, H., Motiwala, T. et al. (2005) 5-Aza-deoxycytidine induces selective degradation of DNA methyltransferase 1 by a proteasomal pathway that requires the KEN box, bromo-adjacent homology domain, and nuclear localization signal. Mol Cell Biol 25: 4727-4741.
27. Gifford, G., Paul, J., Vasey, P.A., Kaye, S.B. and Brown, R. ( 2004) The acquisition of hMLH 1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients. Clin Cancer Res 10: 4420-4426.
28. Glasspool, R.M., Gore, M., Rustin, G., McNeish, I., Wilson, R., Pledge, S. et al. (2009) Randomized phase II study of decitabine in combination with carboplatin compared with carboplatin alone in patients with recurrent advanced ovarian cancer. J Clin Oncol 27: 15s.
29. Glasspool, R.M., Teodoridis, J.M. and Brown, R. ( 2006) Epigenetics as a mechanism driving polygenic clinical drug resistance. Br J Cancer 94: 1087-1092.
30. Graham, J.S., Kaye, S.B. and Brown, R. (2009) The promises and pitfalls of epigenetic therapies in solid tumours. Eur J Cancer 45: 1129-1136.
31. Greenlee, R.T., Hill-Harmon, M.B., Murray, T. and Thun, M. ( 2001) Cancer statistics, 2001. CA Cancer J Clin 51: 15-36.
32. Greenman, C., Stephens, P., Smith, R., Dalgliesh, G.L., Hunter, C., Bignell, G. et al. (2007) Patterns of somatic mutation in human cancer genomes. Nature 446: 153-158.
33. Griffiths, E.A. and Gore, S.D. ( 2008) DNA methyltransferase and histone deacetylase inhibitors in the treatment of myelodysplastic syndromes. Semin Hematol 45: 23-30.
34. Inbal, B., Cohen, O., Polak-Charcon, S., Kopolovic, J., Vadai, E., Eisenbach, L. et al. (1997) DAP kinase links the control of apoptosis to metastasis. Nature 390: 180-184.
35. Issa, J.P. ( 2004) CpG island methylator phenotype in cancer. Nat Rev Cancer 4: 988-993.
36. Issa, J.P. ( 2007) DNA methylation as a therapeutic target in cancer. Clin Cancer Res 13: 1634-1637.
37. Issa, J.P., Garcia-Manero, G., Giles, F.J., Mannari, R., Thomas, D., Faderl, S. et al. (2004) Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies. Blood 103: 1635-1640.
38. Issa, J.P., Gharibyan, V., Cortes, J., Jelinek, J., Morris, G., Verstovsek, S. et al. (2005) Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate. J Clin Oncol 23: 3948-3956.
39. Jones, P.A. and Baylin, S.B. ( 2007) The epigenomics of cancer. Cell 128: 683-692.
40. Karran, P. and Hampson, R. ( 1996) Genomic instability and tolerance to alkylating agents. Cancer Surveys 28: 69-85.
41. Kartalou, M. and Essigmann, J.M. ( 2001) Recognition of cisplatin adducts by cellular proteins. Mutat Res 478: 1-21.
42. Kato, K., Iida, S., Uetake, H., Takagi, Y., Yamashita, T., Inokuchi, M. et al. (2008) Methylated TMS 1 and DAPK genes predict prognosis and response to chemotherapy in gastric cancer. Int J Cancer 122: 603-608.
43. Konstantinopoulos, P.A., Spentzos, D. and Cannistra, S.A. ( 2008) Gene-expression profiling in epithelial ovarian cancer. Nat Clin Pract Oncol 5: 577-587.
44. Lachner, M., O'Sullivan, R.J. and Jenuwein, T. ( 2003) An epigenetic road map for histone lysine methylation. J Cell Sci 116: 2117-2124.
45. Lehmann, U., Celikkaya, G., Hasemeier, B., Langer, F. and Kreipe, H. ( 2002) Promoter hypermethylation of the death-associated protein kinase gene in breast cancer is associated with the invasive lobular subtype. Cancer Res 62: 6634-6638.
46. Li, M., Balch, C., Montgomery, J.S., Jeong, M., Chung, J.H., Yan, P. et al. (2009) Integrated analysis of DNA methylation and gene expression reveals specific signaling pathways associated with platinum resistance in ovarian cancer. BMC Med Genomics 2: 34.
47. Luqmani, Y.A. ( 2005) Mechanisms of drug resistance in cancer chemotherapy. Med Princ Pract 14(Suppl 1): 35-48.
48. Marks, P.A. and Xu, W.S. (2009) Histone deacetylase inhibitors: Potential in cancer therapy. J Cell Biochem 107: 600-608.
49. Matei, D.E. and Nephew, K.P. (2010) Epigenetic therapies for chemoresensitization of epithelial ovarian cancer. Gynecol Oncol 116: 195-201.
50. Miranda, T.B., Cortez, C.C., Yoo, C.B., Liang, G., Abe, M., Kelly, T.K. et al. (2009) DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation. Mol Cancer Ther 8: 1579-1588.
51. Moreland, N.J., Illand, M., Kim, Y.T., Paul, J. and Brown, R. ( 1999) Modulation of drug resistance mediated by loss of mismatch repair by the DNA polymerase inhibitor aphidicolin. Cancer Res 59: 2102-2106.
52. Mund, C., Brueckner, B. and Lyko, F. ( 2006) Reactivation of epigenetically silenced genes by DNA methyltransferase inhibitors: basic concepts and clinical applications. Epigenetics 1: 7-13.
53. Olsen, E.A., Kim, Y.H., Kuzel, T.M., Pacheco, T.R., Foss, F.M., Parker, S. et al. (2007) Phase IIb multi-center trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol 25: 3109-3115.
54. Papouli, E., Cejka, P. and Jiricny, J. ( 2004) Dependence of the cytotoxicity of DNA-damaging agents on the mismatch repair status of human cells. Cancer Res 64: 3391-3394.
55. Plumb, J.A., Steele, N., Finn, P.W. and Brown, R. ( 2004) Epigenetic approaches to cancer therapy. Biochem Soc Trans 32: 1095-1097.
56. Plumb, J.A., Strathdee, G., Sludden, J., Kaye, S.B. and Brown, R. ( 2000) Reversal of drug resistance in human tumor xenografts by 2'-deoxy-5-azacytidineinduced demethylation of the hMLH 1 gene promoter. Cancer Res 60: 6039-6044.
57. Press, J.Z., de Luca, A., Boyd, N., Young, S., Troussard, A., Ridge, Y. et al. (2008) Ovarian carcinomas with genetic and epigenetic BRCA 1 loss have distinct molecular abnormalities. BMC Cancer 8: 17.
58. Ramalingam, S.S., Maitland, M.L., Frankel, P., Argiris, A.E., Koczywas, M., Gitlitz, B. et al. (2010) Carboplatin and Paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancer. J Clin Oncol 28: 56-62.
59. Shimodaira, H., Yoshioka-Yamashita, A., Kolodner, R.D. and Wang, J.Y. ( 2003) Interaction of mismatch repair protein PMS 2 and the p53-related transcription factor p 73 in apoptosis response to cisplatin. Proc Natl Acad Sci U S A 100: 2420-2425.
60. Steele, N., Finn, P., Brown, R. and Plumb, J.A. (2009) Combined inhibition of DNA methylation and histone acetylation enhances gene re-expression and drug sensitivity in vivo. Br J Cancer 100: 758-763.
61. Stewart, D.J., Issa, J.P., Kurzrock, R., Nunez, M.I., Jelinek, J., Hong, D. et al. (2009) Decitabine effect on tumor global DNA methylation and other parameters in a phase I trial in refractory solid tumors and lymphomas. Clin Cancer Res 15: 3881-3888.
62. Stojic, L., Mojas, N., Cejka, P., Di Pietro, M., Ferrari, S., Marra, G. et al. (2004) Mismatch repair-dependent G 2 checkpoint induced by low doses of SN 1 type methylating agents requires the ATR kinase. Genes Dev 18: 1331-1344.
63. Stresemann, C., Brueckner, B., Musch, T., Stopper, H. and Lyko, F. ( 2006) Functional diversity of DNA methyltransferase inhibitors in human cancer cell lines. Cancer Res 66: 2794-2800.
64. Suva, M.L., Riggi, N., Janiszewska, M., Radovanovic, I., Provero, P., Stehle, J.C. et al. (2009) EZH 2 is essential for glioblastoma cancer stem cell maintenance. Cancer Res 69: 9211-9218.
65. Tan, J., Yang, X., Zhuang, L., Jiang, X., Chen, W., Lee, P.L. et al. (2007) Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev 21: 1050-1063.
66. Tang, X., Khuri, F.R., Lee, J.J., Kemp, B.L., Liu, D., Hong, W.K. et al. (2000) Hypermethylation of the death-associated protein (DAP) kinase promoter and aggressiveness in stage I non-small-cell lung cancer. J Natl Cancer Inst 92: 1511-1516.
67. Tang, X., Wu, W., Sun, S.Y., Wistuba, I.I., Hong, W.K. and Mao, L. ( 2004) Hypermethylation of the death-associated protein kinase promoter attenuates the sensitivity to TRAIL-induced apoptosis in human non-small cell lung cancer cells. Mol Cancer Res 2: 685-691.
68. Taniguchi, T., Tischkowitz, M., Ameziane, N., Hodgson, S.V., Mathew, C.G., Joenje, H. et al. (2003) Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors. Nat Med 9: 568-574.
69. Teodoridis, J.M., Hall, J., Marsh, S., Kannall, H.D., Smyth, C., Curto, J. et al. (2005) CpG island methylation of DNA damage response genes in advanced ovarian cancer. Cancer Res 65: 8961-8967.
70. Varambally, S., Dhanasekaran, S.M., Zhou, M., Barrette, T.R., Kumar-Sinha, C., Sanda, M.G. et al. (2002) The polycomb group protein EZH 2 is involved in progression of prostate cancer. Nature 419: 624-629.
71. Wang, D. and Lippard, S.J. ( 2005) Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov 4: 307-320.
72. Warrener, R., Beamish, H., Burgess, A., Waterhouse, N.J., Giles, N., Fairlie, D. et al. (2003) Tumor cell-selective cytotoxicity by targeting cell cycle checkpoints. FASEB J 17: 1550-1552.
73. Wood, L.D., Parsons, D.W., Jones, S., Lin, J., Sjoblom, T., Leary, R.J. et al. (2007) The genomic landscapes of human breast and colorectal cancers. Science 318: 1108-1113.
74. Xu, W.S., Parmigiani, R.B. and Marks, P.A. ( 2007) Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 26: 5541-5552.
75. Yamaguchi, S., Asao, T., Nakamura, J., Ide, M. and Kuwano, H. ( 2003) High frequency of DAP-kinase gene promoter methylation in colorectal cancer specimens and its identification in serum. Cancer Lett 194: 99-105.
76. Yang, N., Kaur, S., Volinia, S., Greshock, J., Lassus, H., Hasegawa, K. et al. (2008) MicroRNA microarray identifies Let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer. Cancer Res 68: 10307-10314.
77. Yoo, C.B. and Jones, P.A. ( 2006) Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discov 5: 37-50.
78. Yoshioka, K., Yoshioka, Y. and Hsieh, P. ( 2006) ATR kinase activation mediated by MutSalpha and MutLalpha in response to cytotoxic O6-methylguanine adducts. Mol Cell 22: 501-510.
79. Yu, J., Rhodes, D.R., Tomlins, S.A., Cao, X., Chen, G., Mehra, R. et al. (2007) A polycomb repression signature in metastatic prostate cancer predicts cancer outcome. Cancer Res 67: 10657-10663.
80. Zhang, S., Balch, C., Chan, M.W., Lai, H.C., Matei, D., Schilder, J.M. et al. (2008) Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res 68: 4311-4320.